The popularity of Viagra initially drove a period of growth for pharma, but recent changes present a uncertain scenario for shareholders. Lower-cost alternatives are eating into revenue, and ongoing legal battles add more risk to the equation. While certain companies might still benefit from complementary services, the overall trend suggests a c… Read More